In view of the prevalence of the dysregulated Hippo pathway in cancer, compounds have been developed to decrease YAP expression (e.g., CA3), block the interaction between YAP/TAZ and TEAD (e.g., verteporfin, bis-aryl hydrazine scaffold, and VGLL4 peptide), or target the palmitoylation pocket of TEAD (e.g., flufenamic acid) [63,64]. Here, YAP1 is linked to cancer.